Merck, Inc.

🇵🇭Philippines

Country: 🇵🇭Philippines

Ownership: Subsidiary

Employees: -

Market Cap: $295.3B

Website: http://www.merck.ph

Clinical Trials

A Study of Pembrolizumab (MK-3475) With or Without V940 in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

Phase 3

Recruiting

Conditions: Carcinoma, Non-Small-Cell Lung

Interventions: Biological: Pembrolizumab
Drug: Cisplatin
Drug: Carboplatin
Drug: Pemetrexed
Drug: Gemcitabine
Drug: Paclitaxel
Biological: V940
Other: Placebo

First Posted Date: 2024-10-02

Last Posted Date: 2024-12-06

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 680

Registration Number: NCT06623422

Locations: 🇺🇸
Beacon Cancer Care ( Site 0127), Post Falls, Idaho, United States
🇺🇸
Thompson Cancer Survival Center ( Site 0168), Knoxville, Tennessee, United States
🇦🇺
Tasman Oncology Research ( Site 2104), Southport, Queensland, Australia

and more 6 locations

Safety and Immunogenicity of V540B in Healthy Adults (V540B-002)

Phase 1

Recruiting

Conditions: Healthy

Interventions: Biological: GARDASIL®9 (G9)
Biological: V540B

First Posted Date: 2024-10-02

Last Posted Date: 2024-12-19

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 72

Registration Number: NCT06623409

Locations: 🇺🇸
Anaheim Clinical Trials ( Site 0002), Anaheim, California, United States
🇺🇸
California Clinical Trials Medical Group managed by PAREXEL ( Site 0008), Glendale, California, United States
🇺🇸
Research Centers of America ( Hollywood ) ( Site 0001), Hollywood, Florida, United States

and more 2 locations

A Study of MK-6552 in Sleep Deprived Healthy Participants (MK-6552-003)

Phase 1

Completed

Conditions: Healthy
Narcolepsy

Interventions: Drug: MK-6552
Drug: MK-6552 placebo
Drug: Modafinil
Drug: Modafinil placebo

First Posted Date: 2024-09-30

Last Posted Date: 2024-09-30

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 18

Registration Number: NCT06619665

Locations: 🇺🇸
NeuroTrials Research Inc (Site 0001), Atlanta, Georgia, United States
🇺🇸
Clinilabs (Site 0003), Eatontown, New Jersey, United States

A Study to Evaluate the Effect of Food, Formulation, and a Proton Pump Inhibitor (PPI) on MK-1084 in Healthy Adult Participants (MK-1084-003)

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: MK-1084
Drug: PPI

First Posted Date: 2024-09-30

Last Posted Date: 2024-09-30

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 56

Registration Number: NCT06619314

Locations: 🇺🇸
Celerion (Site 0001), Lincoln, Nebraska, United States

A Study of MK-8507 and Islatravir (MK-8591) in Healthy Adult Participants (MK-8507-016)

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: MK-8507
Drug: Islatravir

First Posted Date: 2024-09-30

Last Posted Date: 2024-09-30

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 36

Registration Number: NCT06619678

Locations: 🇺🇸
Celerion (Site 0001), Lincoln, Nebraska, United States

A Study to Evaluate Molnupiravir Tablet Formulation Compared to the Molnupiravir Capsule Formulation in Healthy Adult Participants (MK-4482-011)

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Molnupiravir

First Posted Date: 2024-09-27

Last Posted Date: 2024-09-27

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 64

Registration Number: NCT06615869

Locations: 🇺🇸
QPS-MRA, LLC-Early Phase (Site 0002), South Miami, Florida, United States

A Clincal Study of Enlicitide and the Effect of Food in Healthy Adult Participants (MK-0616-033)

Phase 1

Active, not recruiting

Conditions: Healthy

Interventions: Drug: Enlicitide

First Posted Date: 2024-09-24

Last Posted Date: 2024-11-08

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 20

Registration Number: NCT06609512

Locations: 🇺🇸
Celerion ( Site 0001), Tempe, Arizona, United States

A Study of V118 Formulation C (V118C) in Healthy Participants (V118C-001)

Phase 1

Active, not recruiting

Conditions: Healthy

Interventions: Biological: V118C
Biological: V118
Biological: PREVNAR 20™
Biological: Saline

First Posted Date: 2024-09-24

Last Posted Date: 2024-11-25

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 65

Registration Number: NCT06611033

Locations: 🇺🇸
Velocity Clinical Research, Hallandale Beach ( Site 0003), Hallandale Beach, Florida, United States
🇺🇸
Research Centers of America ( Hollywood ) ( Site 0002), Hollywood, Florida, United States
🇺🇸
University of Texas Medical Branch ( Site 0001), Galveston, Texas, United States

A Study to Compare Oral Formulations of Tedizolid Phosphate in Healthy Adults (MK-1986-044)

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Tedizolid Phosphate Oral Formulation 1 (Reference)
Drug: Tedizolid Phosphate Oral Formulation 2 (Test)

First Posted Date: 2024-09-24

Last Posted Date: 2024-09-24

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 18

Registration Number: NCT06609161

Locations: 🇺🇸
Celerion (Site 0001), Lincoln, Nebraska, United States

Study of Patritumab Deruxtecan in Participants With Gastrointestinal Cancers (MK-1022-011)

Phase 1

Recruiting

Conditions: Gastrointestinal Cancer

Interventions: Biological: Patritumab deruxtecan

First Posted Date: 2024-09-19

Last Posted Date: 2024-12-13

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 130

Registration Number: NCT06596694

Locations: 🇨🇱
Centro de Oncología de Precisión ( Site 0305), Santiago, Region M. De Santiago, Chile
🇫🇷
Centre Eugène Marquis Rennes - Centre de Lutte Contre le Cancer ( Site 0501), Rennes, Ille-et-Vilaine, France
🇪🇸
Hospital Clinico San Carlos ( Site 1003), Madrid, Spain

and more 13 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy